| Course | NSG 520 Pathophysiology and Pharmacology |
|---|---|
| Unit | Unit 3 |
| Paper type | Two-science integration case |
| Length | About 1,050 words, 6 pages |
| Format | APA 7 student paper |
| School | Herzing University |
| Program | MSN |
| Updated | October 2026 |
Free sample paper for NSG 520 Unit 3
Albuminuria That Persists on Two Kidney-Protective Drugs: One Line of Reasoning Through Mineralocorticoid Receptor Overactivation and Finerenone
Student Name
Department of Nursing, Herzing University
NSG 520: Pathophysiology and Pharmacology
Instructor Name
February 4, 2026
Albuminuria That Persists on Two Kidney-Protective Drugs: One Line of Reasoning Through Mineralocorticoid Receptor Overactivation and Finerenone
The Patient and the Problem
Mrs. D., the composite woman of 68 with type 2 diabetes and stage 3b chronic kidney disease, has now taken lisinopril 20 mg daily for years and dapagliflozin 10 mg daily for three months. Her estimated glomerular filtration rate dipped from 38 to 35 in the first month, as expected when intraglomerular pressure falls, and has held at 35. Her urine albumin-to-creatinine ratio has fallen from 420 to 310 mg/g, a meaningful improvement but still well above the threshold for severely increased albuminuria. Her potassium is 4.8 mmol/L and her blood pressure 134/80. The question is whether a third agent acting on a different mechanism would further slow her kidney disease, and what it would cost her.
The Mechanism That Remains Untreated
Her two current drugs act on the hemodynamic parts of diabetic kidney disease: lisinopril reduces angiotensin II and with it the efferent constriction that raises glomerular pressure, and dapagliflozin restores tubuloglomerular feedback and reduces afferent dilation. A third process is inflammatory and fibrotic rather than hemodynamic. The mineralocorticoid receptor, activated by aldosterone and, in diabetes, by other signals, is present not only in the collecting duct, where it governs sodium and potassium handling, but also in podocytes, mesangial cells, fibroblasts, and immune cells in the kidney. Overactivation of the receptor in these cells promotes inflammation and fibrosis, contributing to scarring independent of glomerular pressure. Angiotensin-converting enzyme inhibition does not fully prevent this, in part because aldosterone levels can rise again over time despite the inhibitor, and because receptor activation in diabetes is not driven by aldosterone alone.
This is the mechanistic reason a third agent is plausible: her persistent albuminuria may reflect an inflammatory and fibrotic process her current drugs do not directly address.
The Agent Acting on That Mechanism
Finerenone is a nonsteroidal mineralocorticoid receptor antagonist. It blocks the receptor in the kidney's podocytes, mesangial cells, and inflammatory cells, reducing the downstream expression of inflammatory and fibrotic genes. Its nonsteroidal structure gives it high selectivity for the mineralocorticoid receptor, with little binding to androgen or progesterone receptors, so it does not cause the breast enlargement and hormonal effects seen with spironolactone. In a large trial enrolling people who had both type 2 diabetes and kidney disease and were already taking a maximally tolerated renin-angiotensin system blocker, finerenone reduced the risk of a composite kidney outcome, including kidney failure and sustained large declines in filtration, compared with placebo (Bakris et al., 2020). A pooled analysis of that trial and a companion trial found reductions in both cardiovascular and kidney outcomes across a broad range of kidney function (Agarwal et al., 2022). Because it acts on a different mechanism, finerenone's effect is added to, not duplicated by, her current drugs.
The Cost, From the Same Mechanism
The same receptor that finerenone blocks in the kidney's inflammatory cells also drives potassium secretion in the collecting duct. There, aldosterone acting on the mineralocorticoid receptor increases sodium reabsorption through epithelial sodium channels, creating a negative charge in the tubular lumen that drives potassium out of the cell through potassium channels into the urine. Blocking the receptor reduces sodium reabsorption and potassium secretion, so potassium rises. For Mrs. D., whose lisinopril already reduces aldosterone and whose reduced filtration already limits potassium excretion, this is the central risk. In the trials, hyperkalemia was more common with finerenone than with placebo, though it rarely led to stopping treatment when monitored (Bakris et al., 2020).
The dapagliflozin she already takes may partly offset this: sodium-glucose cotransporter 2 inhibitors increase sodium delivery to the distal nephron, which favors potassium secretion, and in practice they have been associated with lower rates of hyperkalemia. The mechanism that creates the risk and the mechanism that eases it are both visible in the same segment of the nephron.
Why Not Spironolactone
A steroidal mineralocorticoid receptor antagonist such as spironolactone also blocks the receptor and costs less, so the choice needs a reason. Spironolactone binds androgen and progesterone receptors as well, which explains its breast tenderness and enlargement, menstrual irregularity, and sexual side effects. Its active metabolites have long half-lives, so potassium rises that develop on it take longer to reverse after the drug is stopped. And the large kidney outcome trials in type 2 diabetes with albuminuria were conducted with finerenone, not spironolactone; spironolactone lowers albuminuria in smaller studies, but its effect on kidney failure in this population has not been shown in a comparable trial. For Mrs. D., the evidence for kidney and cardiovascular outcomes, the shorter action if potassium rises, and the absence of hormonal effects favor finerenone, provided its cost is covered; if it is not, spironolactone at a low dose with close potassium monitoring would be a reasonable alternative, chosen with her understanding of the difference.
The Decision and Its Monitoring
Her potassium of 4.8 mmol/L is below the level at which starting finerenone would be withheld, and her estimated filtration rate of 35 is within the range studied. Current guidance supports adding a nonsteroidal mineralocorticoid receptor antagonist in patients with type 2 diabetes and albuminuria despite a maximally tolerated renin-angiotensin system blocker, when potassium is normal (Rossing et al., 2022). The plan: start finerenone 10 mg daily, the dose used at her level of kidney function; recheck potassium and kidney function at four weeks; increase to 20 mg if potassium remains at or below the level set in the prescribing information and kidney function is stable; and review her diet for high-potassium salt substitutes, which many patients with kidney disease use to reduce sodium without realizing they add potassium. If potassium rises above the threshold for holding, finerenone is held and restarted at the lower dose when potassium falls.
What the Integration Shows
Mrs. D.'s kidney disease has at least three mechanistic components: altered tubuloglomerular feedback, angiotensin-driven glomerular pressure, and mineralocorticoid receptor-driven inflammation and fibrosis. Each of her three drugs acts on one of them, and the main risk of the third follows directly from the same receptor's role in another cell type. Reasoning through the mechanism and the agent together explains both why the drug is added and what must be watched, which a list of indications and side effects would not.
References
Agarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Gebel, M., Ruilope, L. M., & Bakris, G. L. (2022). Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis. European Heart Journal, 43(6), 474-484. https://doi.org/10.1093/eurheartj/ehab777
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., & Filippatos, G. (2020). Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. New England Journal of Medicine, 383(23), 2219-2229. https://doi.org/10.1056/NEJMoa2025845
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., Sadusky, T., Tandon, N., Tuttle, K. R., Wanner, C., Wilkens, K. G., Zoungas, S., & de Boer, I. H. (2022). KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International, 102(5S), S1-S127. https://doi.org/10.1016/j.kint.2022.06.008
What the NSG 520 Unit 3 instructions ask for
Unit 3 asks you to integrate pathophysiology and pharmacology in one patient case. Expect to state the clinical problem, identify the mechanism still untreated, explain how a drug acts on it, explain its main risk from the same mechanism, compare an alternative and make a decision with monitoring. Students often ask how to keep the two sciences connected rather than in separate sections. Use one line of reasoning: what is happening, what drug acts there, what that same action costs. Choose an alternative to compare, since contrast clarifies the choice. Base the decision on the patient's values, such as potassium. Cite the trial that supports the drug.
How the NSG 520 Unit 3 example is put together
The case opens with Mrs. D.'s current regimen, her albumin-to-creatinine ratio and her potassium. The mechanism section explains why her two drugs act on pressure and filtration but leave inflammation and fibrosis untreated. The agent section explains finerenone's action and why its nonsteroidal structure makes it more selective. The cost section shows how the same receptor block in the collecting duct raises potassium. The alternative section explains why spironolactone carries more potassium and hormonal risk for her. The decision section starts finerenone with a potassium threshold and a recheck at four weeks. The final section states what the integration shows: three mechanistic components, each matched to a drug, with one line of reasoning joining the two sciences.
Where the points sit in the NSG 520 Unit 3 rubric
Herzing's rubric for an integration case typically covers the clinical problem, the untreated mechanism, the drug's action, its risk from the same mechanism, the alternative and the decision with monitoring. The link between mechanism, drug action and risk carries the largest share of marks, because that link is what integration means in this course. Problem points reward patient data that show a gap in current treatment. Action criteria look for accurate receptor pharmacology. Risk points go to harm explained by the same receptor rather than listed from a reference. The alternative earns credit when compared fairly on mechanism and risk. Decision points reward potassium thresholds and monitoring dates. Kidney function rechecks are often credited too. The FIDELIO-DKD trial by Bakris and colleagues supports the decision.
NSG 520 Unit 3 help: mistakes that cost points
Integration cases in Unit 3 often slip by describing pathophysiology and pharmacology in separate sections that never meet. Another frequent problem is naming a drug without explaining where it acts. Students often list side effects instead of deriving the main risk from the mechanism. Alternatives are dismissed in a sentence. Potassium thresholds and monitoring are missing. The patient's current drugs, which also raise potassium, are not considered. The trial evidence is not cited. Kidney function is not rechecked after starting. The decision ignores what the patient wants. Finally, keep one line of reasoning, because graders reward a case where the drug's benefit and harm both follow from the same mechanism.
Get a NSG 520 Unit 3 example written to your instructions
Send the Unit 3 instructions and the rubric from your NSG 520 classroom, and name the condition the case should cover. We write a custom example that alternates mechanism and agent inside the same passages, keeps background to what the drug argument uses, and ends on the joins that are weaker than they look. First custom sample free, returned in 24 to 48 hours.
More NSG 520 papers and MSN samples
- NSG 520 Unit 1: Cellular mechanism trace
- NSG 520 Unit 2: Dosing principle worksheet
- NSG 520 Unit 4: Receptor distribution study
- NSG 520 Unit 5: Site of action comparison
- NSG 520 Unit 6: Abnormal value interpretation table
- NSG 520 Unit 7: Plain language mechanism explainer
- NSG 520 Unit 8: Foundational sciences portfolio
- NU 602 Unit 3: Standardized rate comparison
- NU 651 Unit 3: Stakeholder power and interest map
- NU 715 Unit 3: Encounter suitability criteria
- NSG 521 Unit 3: Review of systems record
NSG 520 Unit 3 questions, answered
Can I write the two sciences in separate sections?
Only if the instructions require that format, and even then the pharmacology section should refer back to specific mechanistic steps by name. Where the format is open, interleaving is safer, because the criteria usually reward the connection rather than the coverage. A reader can tell within a page whether the two halves were written together or assembled afterwards.
How much detail does the mechanism need?
Exactly as much as the drug argument uses, and no more. Background beyond that point is where integration cases lose their room, since the joining passages are what carry the credit. If a paragraph of mechanism never gets referred to later, it either needs a pharmacological consequence attached to it or it should come out of the paper.
What if the drug does not target the mechanism I described?
Then say so, because that is a real and gradeable finding. Many agents act downstream of the process a course describes, or on a compensation rather than on the primary defect, and writing that plainly shows more understanding than forcing an alignment. Name what the agent actually acts on and where that sits relative to the mechanism you traced.
Where can I find a free NSG 520 Unit 3 sample paper?
The full NSG 520 Unit 3 integration case is free on this page, from untreated mechanism to finerenone and its monitoring. A case integrating a different mechanism and drug can be prepared on request.
Why add finerenone to an ACE inhibitor and SGLT2 inhibitor?
Those drugs act on kidney pressure and filtration but leave mineralocorticoid-driven inflammation and fibrosis untreated. Finerenone blocks that receptor, with potassium the main risk to monitor, as this sample explains.